Filament Health

Filament Health is a psychedelic extraction and drug discovery company focused on growing botanical psychedelics in controlled environments, conducting genetic research, carrying out extraction and purification methods, and distributing intellectual property (IP) and drug candidates to drug developers and researchers. Filament also focuses on developing psychedelic-based novel drug candidates using its drug development platform while building a robust intellectual property (IP) portfolio.

The company operates a manufacturing and R&D laboratory at the British Columbia Institute of Technology (BCIT), which is Good Manufacturing Practice (GMP)-approved. The lab has also obtained a Health Canada Dealer’s License that allows the propagation, extraction, purification, and production of all controlled psychedelics, including mescaline, harmaline, etc. 

The company conducted clinical trials on two of Filament’s drug candidates in 2021: 1) Phase 1 trial for a non-psilocybin-based formulation in Q4 2021, and 2) Phase 2 trial of a psilocybin-based formulation to treat major depressive disorder (MDD) in the second half of 2021. The clinical trials were conducted in collaboration with the University of California San Francisco (UCSF) under the Translational Psychedelic Research (TrPR) Program. Filament also signed an agreement to license its psilocybin candidate to Cybin Therapeutics in January 2022 for its three upcoming clinical trials.

In March 2023 , the company received FDA approval for a Phase II clinical trial of PEX010, which is a botanical psilocybin drug candidate, at the University of California San Francisco’s Translational Psychedelic Research Program (TrPR). The investigator-initiated trial aims to examine how the drug can be used to treat individuals with methamphetamine use disorder (MAUD). In August 2023 , it received FDA approval for two other clinical trials investigating PEX010. 

Filament Health was up-listed to the OTCQB Venture Market in October 2021—from the OTC Pink Market—under the ticker symbol “FLHLF.” It is also listed on the NEO Exchange under the ticker symbol “FH,” since June 2021, following an amalgamation with 1287396 B.C. Ltd. For FY2022 , the company reported licensing revenues of USD 0.4 million and cash and cash equivalent balance of USD 2.8 million, as of the reporting date.

Key customers and partnerships

In June 2023 , the company entered an exclusive global licensing agreement with NeoLumina Bioscience Inc. to license its botanical psilocybin drug candidate, PEX010, for the development of therapeutics related to eating disorders. Further, in August 2023 , Reset Pharma entered a licensed agreement with the company to use Filament’s botanical psilocybin drug candidate, PEX010, for a FDA-approved Phase II clinical trial studying demoralization syndrome in cancer patients. In July 2024 , the company terminated its agreement with Psyence, which covered the supply and commercialization of PEX010.